Zhishu Biotechnology

Zhishu Biotechnology is dedicated to the research and development of products for repairing central nervous system injuries. It has pioneered a new approach to treating such injuries by activating endogenous neurogenesis to produce new neurons, fundamentally solving the medical challenge of central nervous system repair. This has led to the creation of an innovative product for spinal cord injury treatment—the "Spinal Cord Reconstruction System." Currently, this product has completed validation at the animal level, including non-human primates, undergone "independent third-party verification," 10 IIT clinical trials, and received ethical approval from several authoritative tertiary hospitals in China. It is now preparing to launch registration-based clinical trials. The successful market entry of this product will mark a breakthrough as the first-of-its-kind device in this field both in China and globally, filling a significant gap in world medicine and enabling patients with spinal cord injuries to regain the ability to stand.